Alex Kolicich focuses on IT and Bio-IT investments.

Prior to joining 8VC, Alex was a Partner at Formation 8. Alex has also worked with Peter Thiel as a Principal at Mithril Capital Management, a growth-stage venture fund, where he helped lead investments in AppDirect, C2FO and Helion Energy.

Preceding his venture career, Alex worked as engineer and early-product advisor at Clarium, Palantir, and Google. He was an early member of the Clarium Capital quantitative engineering team (with Joe Lonsdale) and close advisor/collaborator with the early Palantir team; advising on product design and contributing to the product. At Google Research, Alex worked on Google Street-Views before and during launch. Preceding Street-Views, also at Google, he worked on the development and launch of the Google Checkout product.

Chandra P. Leo joined the Private Equity Team of HBM Partners in 2007. His board and investment experience includes biotech and medtech companies such as ChemoCentryx (IPO NASDAQ), ESBATech (acquired by Alcon/Novartis), Homology Medicines (IPO NASDAQ), ObsEva (IPO NASDAQ), Symbiomix Therapeutics (acquired by Lupin), CardiacAssist (acquired by LivaNova) and Gynesonics.

Prior to HBM, Chandra served as a postdoctoral scientist at Stanford University Medical Center, as a physician at the University Hospital Leipzig (Germany) and as a principal in the life sciences team at Wellington Partners. He completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD.

Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.

Dr. Schiff currently serves as a director of Aclaris Therapeutics and Monte Rosa Therapeutics. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Agile Therapeutics, ArgiNOx Pharmaceuticals, ARMGO Pharma, Barrier Therapeutics (acquired by Stiefel Laboratories), Bioenvision (acquired by Genzyme), CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Harmony Biosciences, Miramar Labs (acquired by Sientra), Myogen (acquired by Gilead Sciences), PowerVision (acquired by Alcon), Quintiles (now IQVIA), SkinMedica (acquired by Allergan), Sirion Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by Nabriva) and ZELTIQ Aesthetics (acquired by Allergan). He is a longtime supporter and board member of the Visiting Nurse Service of New York.

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.

Gorjan Hrustanovic, PhD is a Partner at BVF Partners, where he is responsible for overseeing biotech investments for both private and public companies. Dr. Hrustanovic currently serves on the board of directors of Olema Pharmaceuticals, Kymera Therapeutics, Forward Therapeutics, Plexium, and also served on Board of Nimbus Therapeutics and Rain Therapeutics.

Prior to joining BVF in 2015, Dr. Hrustanovic obtained his PhD in cancer biology and cell signaling at the University of California, San Francisco (UCSF), with a primary focus on precision medicine and resistance to targeted therapies in lung cancer. His graduate research led to publications in leading scientific journals such as Nature Medicine and others. Dr. Hrustanovic earned a BS degree in molecular biology, and a BS in economics and management science from the University of California, San Diego.

Robert is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej has 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation.

Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that mircrodoplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013. After the acquisition, Robert directed Novozymes’ Digital Biotechnology unit in San Francisco and lead global biotechnology scouting efforts.

Robert earned his Ph.D. in Bioengineering jointly from UC Berkeley and UC San Francisco. He is a published contributor to the human, drosophila, and canine genome projects.

Dr. Luehrsen is currently a consultant and independent board member at Dren Bio and has over 25 years of experience working with monoclonal antibodies. His prior roles and consulting work include KaloBios, Allakos, Complete Genomics, Omniox, and GPCR Therapeutics. Earlier in his career, Dr. Luehrsen held research positions at Roche, Motorola, and Applied Biosystems. Dr. Luehrsen received his BS and MS in Biology from the University of Illinois Urbana-Champaign, his PhD in Biochemistry from the University of California, Santa Barbara, and completed his postdoctoral training at Stanford University. He has authored over 30 peer-reviewed publications and is an inventor on numerous patents.

Sujal is Co-founder and Managing Director at Juvia Group. Prior to Juvia, he was President, CEO and Director of CymaBay Therapeutics (NASDAQ: CBAY). Sujal led the company's restructuring and recapitalization from 2012-2013 and subsequently took the company public in 2014. Over twelve years, he raised more than $1 billion, led the team that delivered Livdelzi® (seladelpar) for people with primary biliary cholangitis and steered the company's sale to Gilead Sciences for $4.3 billion. Sujal is Chair of the Board of Tvardi Therapeutics and a Director of Soufflé Therapeutics. Earlier in his career, he was a healthcare investment banker at Citigroup and Credit Suisse. Sujal holds an MBA from Carnegie Mellon University’s Tepper School of Business and BS and MS degrees in Biomedical Engineering from Northwestern University.

Shelley Chu, MD, PhD, is a Partner at Lightspeed Venture Partners, where she leads Biotech investing across all stages of discovery and clinical development and co-heads the firm's Healthcare Sector. She brings more than two decades of investing and operating experience in the biopharmaceutical industry, spanning research and development, business development, and commercialization. Previously, Dr. Chu led R&D strategy across all therapeutic areas and business development in immuno-oncology and hepatitis B at Gilead Sciences. Her board experience includes Antares, Diagonal, Enlaza, Odyssey, Seismic, Triana, and Alpha-9 Oncology. She previously served on the boards of Scorpion (acquired by Eli Lilly), Tizona (acquired by Gilead) and IFM (acquired/partnered with Bristol Myers Squibb and Novartis). Dr. Chu received her B.A. in molecular biology from Princeton University and her M.D. and Ph.D. in biochemistry and biophysics from the University of California, San Francisco.